Diversified Trust Co Sells 493 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Diversified Trust Co lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 25.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,455 shares of the pharmaceutical company’s stock after selling 493 shares during the period. Diversified Trust Co’s holdings in Vertex Pharmaceuticals were worth $608,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital World Investors boosted its position in Vertex Pharmaceuticals by 21.3% during the fourth quarter. Capital World Investors now owns 21,805,770 shares of the pharmaceutical company’s stock valued at $8,872,586,000 after acquiring an additional 3,824,103 shares during the last quarter. Norges Bank bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $1,237,877,000. Public Employees Retirement Association of Colorado grew its position in shares of Vertex Pharmaceuticals by 2,272.6% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 434,874 shares of the pharmaceutical company’s stock worth $176,946,000 after buying an additional 416,545 shares during the period. abrdn plc increased its stake in Vertex Pharmaceuticals by 196.0% in the fourth quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock valued at $236,410,000 after purchasing an additional 384,730 shares in the last quarter. Finally, Global Assets Advisory LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $137,975,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

VRTX has been the topic of several research reports. Wells Fargo & Company upped their price objective on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Oppenheimer restated an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target for the company in a report on Thursday, April 11th. Redburn Atlantic initiated coverage on Vertex Pharmaceuticals in a research note on Thursday, June 27th. They set a “buy” rating and a $545.00 price objective on the stock. Finally, UBS Group dropped their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $448.61.

Insider Transactions at Vertex Pharmaceuticals

In related news, CEO Reshma Kewalramani sold 1,565 shares of the stock in a transaction on Friday, May 24th. The shares were sold at an average price of $457.00, for a total transaction of $715,205.00. Following the transaction, the chief executive officer now owns 121,374 shares of the company’s stock, valued at approximately $55,467,918. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Vertex Pharmaceuticals news, EVP Edward Morrow Atkinson III sold 7,288 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total value of $3,483,664.00. Following the completion of the sale, the executive vice president now owns 15,972 shares in the company, valued at $7,634,616. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Reshma Kewalramani sold 1,565 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00. Following the completion of the transaction, the chief executive officer now owns 121,374 shares in the company, valued at approximately $55,467,918. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,366 shares of company stock worth $13,058,787. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:VRTX opened at $470.28 on Thursday. The firm has a market capitalization of $121.36 billion, a PE ratio of 30.52, a price-to-earnings-growth ratio of 2.41 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a 52-week low of $335.82 and a 52-week high of $486.42. The firm has a fifty day moving average of $447.69 and a 200 day moving average of $427.70.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. The company had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. Vertex Pharmaceuticals’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $2.67 EPS. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.